Tectonic Therapeutic has finished filling the trial that now carries the equity. The lead asset is a long-acting relaxin fusion aimed at Group 2 pulmonary hypertension, a setting with no approved therapy and a large untreated pool in the United States. Enrollment in the global APEX Phase 2 study closed in June, and an independent data committee later reviewed unblinded safety and efficacy covering most of the planned exposure and let the study continue unchanged. That combination converts the story from whether the trial can even recruit the harder combined pre- and post-capillary phenotype into whether the acute hemodynamic signal survives a full placebo-controlled treatment period.
The cash account still covers the readout. Mid-year cash sat at $227 million after a modest at-the-market tap. Management has guided that stack into early 2029, through APEX, the smaller interstitial-lung-disease study, and the next TX2100 steps. Operating spend is rising, but the rise is concentrated in contract research for the two TX45 Phase 2 programs rather than in a pre-commercial build. The second asset, an APJ antagonist for hereditary hemorrhagic telangiectasia, has only finished healthy-volunteer single-dose cohorts. It is a real option, not a second binary of equal weight.
What the market is paying for is a funded call on APEX, not a platform franchise. The September 18 close sat near $27. That price capitalizes the firm at roughly $528 million. Enterprise value after cash is about $301 million. That is a restrained probability on a first-in-class Group 2 asset if one takes the company's own large peak-sales language at face value. The open question for the next two quarters is whether the late 2026 TX2100 healthy-volunteer readout and the early 2027 APEX topline confirm that the Phase 1b hemodynamics were a durable drug effect rather than a catheter-lab snapshot.